Cost-effectiveness of sirolimus-eluting stents compared with vascular brachytherapy for the treatment of in-stent restenosis

American Heart Journal

Volumn 154, Issue 6, 2007, Pages 1221-1227

  Reynolds, Matthew R ^a,b   Pinto, Duane S ^a   Shi, Chunxue ^b   Walczak, Joshua ^b   Berezin, Ronna ^b   Holmes Jr , David R ^c   Cohen, David J ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAPAMYCIN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEALTH ECONOMICS; HEART CATHETERIZATION; HOSPITAL BILLING; HOSPITAL COST; HOSPITALIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; OUTPATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVASCULARIZATION; TECHNICAL AID;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BRACHYTHERAPY; CORONARY RESTENOSIS; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH RESOURCES; HEART CATHETERIZATION; HUMANS; MALE; MIDDLE AGED; SIROLIMUS;

EID: 36148964074     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.07.033     Document Type: Article

References (23)

1. Waksman R., White R.L., Chan R.C., et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 101 (2000) 2165-2171
2. Leon M.B., Teirstein P.S., Moses J., et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 344 (2001) 250-256
3. Popma J.J., Suntharalingam M., Lansky A.J., et al. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation 106 (2002) 1090-1096
4. Holmes D.R., Teirstein P., Satler L., et al. Sirolimus-eluting stents vs. vascular brachytherapy for in-stent restenosis within bare-metal stents. The SISR randomized trial. JAMA 295 (2006) 1264-1273
5. Cohen D.J., Krumholz H.M., Sukin C.A., et al. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty: results from a randomized clinical trial. Circulation 92 (1995) 2480-2487
6. Eisenberg J. Clinical economics: a guide to the economic analysis of clinical practices. JAMA 262 (1989) 2879-2886
7. Taira D.A., Seto T.B., Siegrist R., et al. Comparison of analytic approaches for the economic evaluation of new technologies alongside multicenter clinical trials. Am Heart J 145 (2003) 452-458
8. Red book (2002), Thomson PDR, Montvale (NJ)
9. Hsiao W.C., Braun P., Dunn D., et al. Results and policy implications of the resource-based relative-value study. New Engl J Med 319 (1988) 881-888
10. Efron B. An introduction to the bootstrap (1993), Chapman & Hall, New York (NY)
11. Rinfret S., Grines C.L., Cosgrove R.S., et al. Quality of life after balloon angioplasty or stenting for acute myocardial infarction. One-year results from the Stent-PAMI trial. J Am Coll Cardiol 38 (2001) 1614-1621
12. Weaver W.D., Reisman M.A., Griffin J.J., et al. Optimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. Lancet 355 (2000) 2199-2203
13. Cohen D.J., Taira D.A., Berezin R., et al. Cost-effectiveness of coronary stenting in acute myocardial infarction: results from the Stent Primary Angioplasty in Myocardial Infarction (Stent-PAMI) Trial. Circulation 104 (2001) 3039-3045
14. Cohen D.J., Cosgrove R.S., Berezin R.H., et al. Cost effectiveness of gamma radiation for treatment of in-stent restenosis: results from the Gamma-1 trial. Circulation 106 (2002) 691-697
15. Serruys P.W., Unger F., Sousa J.E., et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344 (2001) 1117-1124
16. Serruys P.W., van Hout B., Bonnier H., et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 352 (1998) 673-681
17. Lothgren M., and Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9 (2000) 623-630
18. Greenberg D., Bakhai A., Neumann P.J., et al. Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study. Health Policy 70 (2004) 207-216
19. Waksman R., Ajani A.E., White R.L., et al. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis. Circulation 109 (2004) 340-344
20. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
21. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
22. Lagerqvist B., James S.K., Stenestrand U., et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 356 (2007) 1009-1019
23. Pinto D.S., Stone G.W., Ellis S.G., et al. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 48 (2006) 32-36